VEGFA Protein (Transcript Variant 1)

N° du produit ABIN2735219

Protéine Recombinant VEGFA exprimée dans Yeast (Pichia pastoris).

Aperçu rapide pour VEGFA Protein (Transcript Variant 1) (ABIN2735219)

Antigène: VEGFA (Vascular Endothelial Growth Factor A (VEGFA))

Type de proteíne: Recombinant

Origine: Humain

Source: Yeast (Pichia pastoris)

Application: Antibody Production (AbP), Standard (STD)

Pureté: > 95 % as determined by SDS-PAGE and Coomassie blue staining

Détail du produit

Attributs du protein: Transcript Variant 1

Attributs du produit:

• Recombinant human VEGF-A (transcript variant 1) protein expressed in Pichia Pastoris.
• Produced with end-sequenced ORF clone

Information d'application

Indications d'application: Recombinant human proteins can be used for:
Native antigens for optimized antibody production
Positive controls in ELISA and other antibody assays

Restrictions: For Research Use only

Stockage

Concentration: 50 μg/mL

Buffer: Lyophilized from a sterile solution containing 1xPBS, pH 7.4

Stock: -80 °C

Stockage commentaire: Store at -80°C. Thaw on ice, aliquot to individual single-use tubes, and then re-freeze immediately. Only 2-3 freeze thaw cycles are recommended.

Détail du antigène

Antigène: VEGFA (Vascular Endothelial Growth Factor A (VEGFA))

Autre désignation: Vegf-A

Sujet: This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site.

Poids moléculaire: 23.9 kDa

NCBI Accession: NP_001020537

Pathways: Signalisation RTK, Glycosaminoglycan Metabolic Process, Regulation of Cell Size, Tube Formation, Signaling Events mediated by VEGFR1 and VEGFR2, Platelet-derived growth Factor Receptor Signaling, VEGFR1 Specific Signals, VEGF Signaling